β-adrenoceptor blockers increase cardiac sympathetic innervation by inhibiting autoreceptor suppression of axon growth

Journal of Neuroscience

Volumn 30, Issue 37, 2010, Pages 12446-12454

  Clarke, Gwenaëlle L ^a   Bhattacherjee, Aritra ^a   Tague, Sarah E ^a   Hasan, Wohaib ^a,b   Smith, Peter G ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; AMPT; AUTORECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; ISOPRENALINE; METIROSINE; METOPROLOL; NORADRENALIN; PHENTOLAMINE; PROPRANOLOL; TYRAMINE; UNCLASSIFIED DRUG; GROWTH INHIBITOR;

AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GROWTH INHIBITION; HEART; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE CONTRACTILITY; IMMUNOHISTOCHEMISTRY; MEAN ARTERIAL PRESSURE; MOBILIZATION; NERVE CELL CULTURE; NERVE FIBER GROWTH; NERVE SPROUTING; NOISE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RAT; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; SYMPATHETIC NERVE CELL; ANIMAL; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GROWTH CONE; GROWTH, DEVELOPMENT AND AGING; INNERVATION; NERVE CELL INHIBITION; NERVE FIBER; NEWBORN; PHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; AUTORECEPTORS; AXONS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GROWTH CONES; GROWTH INHIBITORS; HEART; NEURAL INHIBITION; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHETIC FIBERS, POSTGANGLIONIC; UP-REGULATION;

EID: 77956817139     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1667-10.2010     Document Type: Article

References (49)

1. Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB (1980) Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65:949-957.
2. Ablad B, Borg KO, Carlsson E, Ek L, Johnson G, Malmfors T, Regardh CG (1975) A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) 36 [Suppl 5]:7-23.
3. Abrahamsson B, Lücker P, Olofsson B, Regårdh CG, Sandberg A, Wieselgren I, Bergstrand R (1990) The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 30:S46-S54.
4. Brunton L, Lazo J, Parker K (2005) Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill.
5. Butler CK, Smith FM, Nicholson J, Armour JA (1990) Cardiac effects induced by chemically activated neurons in canine intrathoracic ganglia. Am J Physiol 259:H1108-H1117.
6. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, Chen PS, Chen LS (2000) Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 101:1960-1969.
7. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG (2008) Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 149:3452-3460.
8. Cohen-Solal A, Rouzet F, Berdeaux A, Le Guludec D, Abergel E, Syrota A, Merlet P (2005) Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 46:1796-1803.
9. Colangelo AM, Follesa P, Mocchetti I (1998) Differential induction of nerve growth factor and basic fibroblast growth factor mRNA in neonatal and aged rat brain. Brain Res Mol Brain Res 53:218-225.
10. Conlon D, Johnston A, Turner P, O'Malley K, Kilfeather S (1991) Hepatic beta-adrenoceptor adaptation during propranolol administration is impaired in aging rats. Eur J Pharmacol 208:323-330.
11. Dal Toso R, De Bernardi MA, Costa E, Mocchetti I (1987) Beta-adrenergic receptor regulation of NGF-mRNA content in rat C6-2B glioma cells. Neuropharmacology 26:1783-1786.
12. Deegan R, He HB, Krivoruk Y, Wood AJ, Wood M (1995) Regulation of norepinephrine release by beta 2-adrenergic receptors during halothane anesthesia. Anesthesiology 82:1417-1425.
13. DiBona GF, Sawin LL (1999) Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. Circulation 100:82-86.
14. Dollery CT, Maling TJ (1979) Beta-blocker withdrawal syndrome. Br Med J 2:1074-1075.
15. Germino FW (2009) The management and treatment of hypertension. Clin Cornerstone 9 [Suppl 3]:S27-S33.
16. Harrison DC, Alderman EL (1976) Editorial: Discontinuation of propranolol therapy: cause of rebound angina pectoris and acute coronary events. Chest 69:1-2.
17. Hasan W, Jama A, Donohue T, Wernli G, Onyszchuk G, Al-Hafez B, Bilgen M, Smith PG (2006) Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Res 1124:142-154.
18. Haydon PG, McCobb DP, Kater SB (1984) Serotonin selectively inhibits growth cone motility and synaptogenesis of specific identified neurons. Science 226:561-564.
19. Hedberg A, Isaksson O, Lundgren B (1980) Sustained cardiac beta adrenoceptor blockade in vitro and increased vulnerability to aconitine-induced arrhythmias in vivo after propranolol withdrawal in rats. J Pharmacol Exp Ther 214:664-669.
20. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79:483-490.
21. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang CS (1993) Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88:1299-1309.
22. Hoeks SE, Scholte Op Reimer WJ, van Urk H, Jörning PJ, Boersma E, Simoons ML, Bax JJ, Poldermans D (2007) Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 33:13-19.
23. Hunt SA (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46:e1-82.
24. Ibarretxe G, Perrais D, Jaskolski F, Vimeney A, Mulle C (2007) Fast regulation of axonal growth cone motility by electrical activity. J Neurosci 27:7684-7695.
25. Ichihara A, Suzuki H, Murakami M, Naitoh M, Matsumoto A, Saruta T (1995) Interactions between angiotensin II and norepinephrine on renin release by juxtaglomerular cells. Eur J Endocrinol 133:569-577.
26. Jiang H, Lu Z, Yu Y, Zhao D, Jian X, Yang B, Huang C (2007) Effects of metoprolol on sympathetic remodeling and electrical remodeling at infarcted border zone after myocardial infarction in rabbits. Cardiology 108:176-182.
27. Kaye DM, Vaddadi G, Gruskin SL, Du XJ, Esler MD (2000) Reduced myocardial nerve growth factor expression in human and experimental heart failure. Circ Res 86:E80-E84.
28. Kondo M, Fujiwara T, Tabei R (1996) Noradrenergic hyperinnervation in the heart of stroke-prone spontaneously hypertensive rats (SHRSP). Hypertens Res 19:69-73.
29. Landis SC (1978) Growth cones of cultured sympathetic neurons contain adrenergic vesicles. J Cell Biol 78:R8-R14.
30. Lefkowitz RJ (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25:413-422.
31. Li W, Knowlton D, Van Winkle DM, Habecker BA (2004) Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons. Am J Physiol Heart Circ Physiol 286:H2229-H2236.
32. Mattson MP, Dou P, Kater SB (1988) Outgrowth-regulating actions of glutamate in isolated hippocampal pyramidal neurons. J Neurosci 8:2087-2100.
33. McCobb DP, Haydon PG, Kater SB (1988) Dopamine and serotonin inhibition of neurite elongation of different identified neurons. J Neurosci Res 19:19-26.
34. Merlet P, Pouillart F, Dubois-Randé JL, Delahaye N, Fumey R, Castaigne A, Syrota A (1999) Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 40:224-231.
35. Miller RR, Olson HG, Amsterdam EA, Mason DT (1975) Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 293:416-418.
36. Nattel S, Rangno RE, Van Loon G (1979) Mechanism of propranolol withdrawal phenomena. Circulation 59:1158-1164.
37. Pacher P, Nagayama T, Mukhopadhyay P, Bátkai S, Kass DA (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3:1422-1434.
38. Rodriguez-Ospina L, Montano-Soto L (2008) Management of chronic stable angina pectoris. Bol Asoc Med P R 100:39-47.
39. Scott TM, Pang SC (1983) The correlation between the development of sympathetic innervation and the development of medial hypertrophy in jejunal arteries in normotensive and spontaneously hypertensive rats. J Auton Nerv Syst 8:25-32.
40. Steinle JJ, Smith PG (2002) Role of adrenergic receptors in vascular remodelling of the rat choroid. Br J Pharmacol 136:730-734.
41. Takahashi H, Ogata H, Kashiwada K, Ohira M, Someya K (1993) Dosing rate-dependent relationship between propranolol plasma concentration and beta-blockade. J Pharmacol Exp Ther 265:681-689.
42. Toyama T, Hoshizaki H, Seki R, Isobe N, Adachi H, Naito S, Oshima S, Taniguchi K (2003) Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 44:1604-1611.
43. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L, Piippo K, Lupoglazoff JM, Villain E, Priori SG, Napolitano C, Zhang L (2009) High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures." Circulation 119:215-221.
44. Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B (1995) Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 25:1327-1332.
45. Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, Cheng H (2004) Sustained beta1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling pathway. Circ Res 95:798-806.
46. Watson-Wright W, Boudreau G, Cardinal R, Armour JA (1991) Beta 1- and beta 2-adrenoceptor subtypes in canine intrathoracic efferent sympathetic nervous system regulating the heart. Am J Physiol 261:R1269-R1275.
47. Wernli G, Hasan W, Bhattacherjee A, van Rooijen N, Smith PG (2009) Macrophage depletion suppresses sympathetic hyperinnervation following myocardial infarction. Basic Res Cardiol 104:681-693.
48. Whitaker-Azmitia PM, Azmitia EC (1986) Autoregulation of fetal serotonergic neuronal development: role of high affinity serotonin receptors. Neurosci Lett 67:307-312.
49. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371.